CREGANNA MEDICAL acquired by TE CONNECTIVITY

The global life sciences leader has successfully finalized a definitive agreement to acquire the total share capital of the target from a consortium led by a prominent European private equity firm and a Canadian institutional investor. This strategic transaction represents a transformative integration for the group’s specialized animal health division, marking a definitive shift toward a data-driven service model. The strategic rationale for the move centers on the convergence of the animal intelligence and animal health industries, where the target’s digitally connected identification and monitoring products provide a significant competitive advantage.

CVC Capital Partners acquired 100% of DOC Generici from Charterhouse Capital Partners, outbidding other major PE firms like Blackstone in a competitive auction. The transaction was supported by a debt package provided by UniCredit and HSBC. The deal represented a highly successful exit for Charterhouse, which reportedly achieved an Internal Rate of Return (IRR) of 40% and a 2.7x money multiple on its 2013 investment. CVC's strategy for the investment was to leverage DOC's dominant market share and asset-light structure to drive organic growth as generic penetration in Italy continued to increase towards European averages.

Astorg and Goldman Sachs have completed the acquisition of HRA Pharma, signaling a major professionalization phase for the niche pharmaceutical laboratory. The strategic rationale for this transaction hinges on an "international-acceleration" maneuver, merging the target’s technical operational depth in hormonal health with the sponsors’ massive global network and institutional resources. This structural alignment provides the organization with the strategic hardware and capital necessary to target aggressive expansion into the United States and other high-potential global markets. The move specifically leverages the target's unique Rx-to-OTC switch prowess, a high-barrier technical capability that transforms clinical assets into scalable consumer brands. By incorporating the sponsors' strategic discipline, the group is now positioned to pivot from a European-centric leader to a global champion in the women’s health segment.

The acquisition of Naturwohl by Perrigo marks a major categorical advancement for the organization’s European self-care division. The strategic logic of this transaction hinges on a "category-entry" maneuver, merging the target’s technical operational depth in the weight management and dietary supplement space with the acquirer’s established pan-European distribution network and the commercial infrastructure of Omega Pharma. This structural alignment provides the combined entity with the marketing hardware and scientific talent necessary to address the increasing consumer demand for preventative health and nutritional optimization.

BC Partners reached an agreement to acquire a majority stake in Pharmathen, partnering with the company's founders who retain a minority shareholding and remain actively involved in the business. The investment thesis centres on leveraging Pharmathen's strong existing platform to pursue selective bolt-on acquisitions, accelerate new product development, and drive international expansion in the growing complex generics pharmaceutical sector. BC Partners intends to support Pharmathen in its ambition to transition from an established European champion into a global pharmaceutical player.

Perrigo has completed the acquisition of Omega Pharma. This transaction acts as a massive "commercial accelerator," solving the complex logistical and regulatory barriers inherent in the European pharmacy landscape. By internalizing a sophisticated thirty-five-country distribution network, the group eliminates its dependency on regional third-party agents and secures immediate shelf-space for its expansive US-developed product pipeline. The strategic rationale hinges on the synergy between localized branding expertise and centralized manufacturing scale. While the acquirer provides the industrial backbone and cost-efficiency of a global supplier, the target brings the technical operational depth required to navigate diverse European healthcare systems and consumer preferences.

Qualium Investissement won the auction process to acquire IMV Technologies, beating competitors LBO France and Florac. This transaction ends the tenure of Pragma Capital (majority owner since 2010), as well as minority investors Cathay Capital and Eurazeo PME. The acquisition is supported by a unitranche debt facility provided by Ardian, representing a leverage of over 5.0x EBITDA. The strategic focus remains on international expansion.

Ceva announced the entry of Merieux Developpement (investment arm of Institut Merieux) into its capital, finalizing the syndicate for its fourth LBO. Merieux joins Asian investors Temasek and CDH Investments, as well as French funds Sagard, Euromezzanine, and Sofiproteol. The strategic rationale is to leverage Institut Merieux's scientific network to fight emerging diseases and antibiotic resistance, and to accelerate Ceva's expansion in Asia (China).

The deal involves the carve-out of Rexam's healthcare devices and prescription retail divisions, which will be acquired by Montagu Private Equity. The transaction is subject to regulatory approval and is expected to be completed in the coming weeks. The strategic rationale behind the deal is to create a standalone company that can focus on the healthcare sector and leverage Montagu Private Equity's expertise and resources to drive growth and expansion. The deal is expected to enhance the competitiveness of the company and improve its market position, while also providing opportunities for innovation and investment in new products and technologies. The company's management team will work closely with Montagu Private Equity to develop a growth strategy that builds on the company's strengths and addresses the evolving needs of the healthcare market. With a strong foundation in place, the company is well-positioned to capitalize on emerging trends and opportunities in the healthcare sector, including the growing demand for innovative medical devices and pharmaceutical packaging solutions.

Five Arrows Managers acquired a stake in Dominique Dutscher to facilitate a partial cash-out for the founder, Dominique Dutscher. While the exact percentage was undisclosed at the time, the deal structure was a classic Owner Buy-Out (OBO), allowing the founder to secure some wealth while remaining invested to drive the next phase of growth. The transaction was financed with senior debt provided by a pool of three banks.